Answer to Question 1
Correct Answer: 4
Rationale 1: Alpha receptors are not located on the swallowing muscles and have no effect on swallowing.
Rationale 2: Beta-adrenergic blockers, and not alpha-adrenergic blockers, have an effect on the beta receptors present in the eye, so alpha1-antagonist therapy has no effect on vision.
Rationale 3: Alpha1-antagonist therapy can cause increased urinary frequency due to more active smooth muscle contractions in the urinary tract.
Rationale 4: The first-dose phenomenon causes syncope due to reduced blood flow to the brain, and so attacks of dizziness and faintness can occur.
Global Rationale: The first-dose phenomenon causes syncope due to reduced blood flow to the brain, and so attacks of dizziness and faintness can occur. Alpha receptors are not located on the swallowing muscles and have no effect on swallowing. Beta-adrenergic blockers, and not alpha-adrenergic blockers, have an effect on the beta receptors present in the eye, so alpha1-antagonist therapy has no effect on vision. Alpha1-antagonist therapy can cause increased urinary frequency due to more active smooth muscle contractions in the urinary tract.
Answer to Question 2
Correct Answer: 1,2,3,5
Rationale 1: All intravenous adrenergic infusions should be administered with an infusion pump.
Rationale 2: The site should be frequently assessed for extravasation.
Rationale 3: The intravenous infusion should be immediately stopped if signs of extravasation occur.
Rationale 4: Raising the head of the bed is an intervention for dyspnea.
Rationale 5: Urinary retention should be reported immediately.
Global Rationale: All intravenous adrenergic infusions should be administered with an infusion pump. The site should be frequently assessed for extravasation. The intravenous infusion should be immediately stopped if signs of extravasation occur. Urinary retention should be reported immediately. Raising the head of the bed is an intervention for dyspnea and is not necessary when administering an infusion of this medication.